FDA To Toughen OTC Oversight, Seek New Authority In Wake Of J&J Recalls

FDA will monitor more closely OTC manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare